Acadia Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
ALKERMES USD 146.5M 168.54M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Corcept Therapeutics USD 178.93M 745K 2024-12
Cytokinetics -160545000 81.19M 2024-09
Eisai JPY 170.21B 16.72B 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Incyte USD 1.1B 38.34M 2024-12
Intra Cellular Therapies USD 178.82M 18.75M 2024-12
J&J USD 15.41B 102M 2024-12
Moderna USD 420M 1.14B 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Pfizer USD 12.11B 718M 2024-12
Prothena -59001000 66.45M 2024-09
PTC Therapeutics USD 196.89M 10.95M 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Acadia Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.